was rising in the premarket after the company named two former Dupont Pharmaceuticals executives to top posts.
The Los Angeles marketer of genetic databases named Paul Friedman chief executive, replacing Roy Whitfield, who was appointed Incyte's chairman. Friedman was previously president of Dupont Pharmaceuticals Research Laboratories.
The company also named Robert Stein president and chief scientific officer. Stein was Dupont Pharmaceuticals' executive vice president of research and preclinical development.
Dupont Pharmaceuticals was sold by